Chugai announces $92 million research deal with Osaka University

19 May 2016

Japanese drug major Chugai Pharmaceutical (TYO: 4519) has announced a research collaboration with the Osaka University Immunology Frontier Research Center (IFReC).

Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX), will provide almost $92 million to fund independent research projects at the IFReC, and expects the partnership to lead to the unprecedented discovery of innovative novel drugs in the field of immunology.

Headed by director Shizuo Akira, an eminent immunologist, IFReC convenes around 30 of the world’s top-class principal investigators from Japan and overseas in the fields of immunology, live imaging and bioinformatics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK